Ignite Creation Date:
2024-05-06 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 2:16 PM
Study NCT ID:
NCT05098405
Status:
TERMINATED
Last Update Posted:
2024-02-15
First Post:
2021-09-30
Brief Title:
First-in-human Safety and Tolerability of MP0317 in Patients With RelapsedRefractory Advanced Solid Tumors
Sponsor:
Molecular Partners AG
Organization:
Molecular Partners AG
Study Overview
Official Title:
A Phase 1 First-in-human Multicenter Open-label Dose-escalation Study to Characterize the Safety and Tolerability of MP0317 in Patients With RelapsedRefractory Advanced Solid Tumors
Status:
TERMINATED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
After completion of the dose-escalation part of the study the safety profile of MP0317 in monotherapy is considered adequately characterized in the dose-escalation part of the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is investigating a new experimental therapy MP0317 a DARPin drug candidate targeting fibroblast activation protein FAP and CD40 Preclinical studies suggest that MP0317 may provide benefit for the treatment of tumors known to express high levels of FAP and for which approved therapies have been exhausted This is the first study of MP0317 in humans and its main purpose is to test its safety and tolerability in patients with advanced solid tumors This study will also examine the blood levels of MP0317 at several increasing dose levels and a recommended dose for further development will be determined The recommended dose will be tested in a second part of the study to confirm safety and to further assess the preliminary biologic and anti-tumor activity
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-005516-22 | EUDRACT_NUMBER | None | None |